IL13 and chronic rhinosinusitis with nasal polyps: Dupilumab, a human monoclonal antibody targeting IL-4 and IL-13, has emerged as the first biologic approved in Italy for CRSwNP, offering significant experience in real-life settings compared to other biologics like omalizumab and mepolizumab [12].